7 Einträge gefunden

1. Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting.

   1. Klyuchnikov, Evgeny
   2. Holler, Ernst
   3. Bornhäuser, Martin
   4. Kobbe, Guido
   5. Nagler, Arnon
   6. Shimoni, Avichai
   7. Könecke, Christian

   2012 - Forschungsinformationssystem des UKE
2. Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation.

   1. Kröger, Nicolaus
   2. Shimoni, Avichai
   3. Schilling, Georgia
   4. Schwerdtfeger, Rainer
   5. Bornhäuser, Martin
   6. Nagler, Arnon
   7. Zander, Axel R.

   2010 - Forschungsinformationssystem des UKE
3. Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up.

   1. Shimoni, Avichai
   2. Hardan, Izhar
   3. Ayuketang Ayuk, Francis
   4. Schilling, Georgia
   5. Atanackovic, Djordje
   6. Zeller, Wolfgang
   7. Yerushalmi, Ronit

   2010 - Forschungsinformationssystem des UKE
4. Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma.

   1. Kröger, Nicolaus
   2. Shaw, Bronwen
   3. Iacobelli, Simona
   4. Zabelina, Tatjana
   5. Peggs, Karl
   6. Shimoni, Avichai
   7. Nagler, Arnon

   2005 - Forschungsinformationssystem des UKE
5. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.

   1. Kröger, Nicolaus-Martin
   2. Perez-Simon, Jose A
   3. Myint, Han
   4. Klingemann, Hans
   5. Shimoni, Avichai
   6. Nagler, Arnon
   7. Martino, Rodrigo

   2004 - Forschungsinformationssystem des UKE
6. Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation.

   1. Kröger, Nicolaus-Martin
   2. Schilling, Georgia
   3. Einsele, Hermann
   4. Liebisch, Peter
   5. Shimoni, Avichai
   6. Nagler, Arnon
   7. Perez-Simon, Jose A

   2004 - Forschungsinformationssystem des UKE
7. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma.

   1. Kröger, Nicolaus-Martin
   2. Shimoni, Avichai
   3. Zagrivnaja, Maria
   4. Ayuketang Ayuk, Francis
   5. Lioznov, Michael
   6. Schieder, Heike
   7. Renges, Helmut-Hans

   2004 - Forschungsinformationssystem des UKE